GH
Price
$48.06
Change
-$0.35 (-0.72%)
Updated
Jun 6 closing price
Capitalization
2.46B
54 days until earnings call
RGEN
Price
$128.30
Change
+$1.60 (+1.26%)
Updated
Jun 6 closing price
Capitalization
10.26B
59 days until earnings call
Interact to see
Advertisement

GH vs RGEN

Header iconGH vs RGEN Comparison
Open Charts GH vs RGENBanner chart's image
Guardant Health
Price$48.06
Change-$0.35 (-0.72%)
Volume$2.07M
Capitalization2.46B
Repligen
Price$128.30
Change+$1.60 (+1.26%)
Volume$600.68K
Capitalization10.26B
GH vs RGEN Comparison Chart
Loading...
GH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GH vs. RGEN commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GH is a Buy and RGEN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (GH: $48.06 vs. RGEN: $128.30)
Brand notoriety: GH: Notable vs. RGEN: Not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GH: 89% vs. RGEN: 69%
Market capitalization -- GH: $2.46B vs. RGEN: $10.26B
GH [@Medical Specialties] is valued at $2.46B. RGEN’s [@Medical Specialties] market capitalization is $10.26B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.52B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GH’s FA Score shows that 0 FA rating(s) are green whileRGEN’s FA Score has 1 green FA rating(s).

  • GH’s FA Score: 0 green, 5 red.
  • RGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, both GH and RGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GH’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 5 bullish TA indicator(s).

  • GH’s TA Score: 4 bullish, 6 bearish.
  • RGEN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RGEN is a better buy in the short-term than GH.

Price Growth

GH (@Medical Specialties) experienced а +18.32% price change this week, while RGEN (@Medical Specialties) price change was +8.66% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.46%. For the same industry, the average monthly price growth was +5.98%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

GH is expected to report earnings on Jul 31, 2025.

RGEN is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (+2.46% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGEN($10.3B) has a higher market cap than GH($2.47B). GH YTD gains are higher at: 57.316 vs. RGEN (-10.866). RGEN has higher annual earnings (EBITDA): 134M vs. GH (-433.3M). GH has more cash in the bank: 1.17B vs. RGEN (751M). RGEN has less debt than GH: RGEN (712M) vs GH (1.35B). RGEN has higher revenues than GH: RGEN (639M) vs GH (564M).
GHRGENGH / RGEN
Capitalization2.47B10.3B24%
EBITDA-433.3M134M-323%
Gain YTD57.316-10.866-527%
P/E RatioN/A247.52-
Revenue564M639M88%
Total Cash1.17B751M156%
Total Debt1.35B712M190%
FUNDAMENTALS RATINGS
GH vs RGEN: Fundamental Ratings
GH
RGEN
OUTLOOK RATING
1..100
177
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
3980
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GH's Valuation (67) in the Medical Or Nursing Services industry is in the same range as RGEN (95) in the Biotechnology industry. This means that GH’s stock grew similarly to RGEN’s over the last 12 months.

GH's Profit vs Risk Rating (100) in the Medical Or Nursing Services industry is in the same range as RGEN (100) in the Biotechnology industry. This means that GH’s stock grew similarly to RGEN’s over the last 12 months.

RGEN's SMR Rating (90) in the Biotechnology industry is in the same range as GH (100) in the Medical Or Nursing Services industry. This means that RGEN’s stock grew similarly to GH’s over the last 12 months.

GH's Price Growth Rating (39) in the Medical Or Nursing Services industry is somewhat better than the same rating for RGEN (80) in the Biotechnology industry. This means that GH’s stock grew somewhat faster than RGEN’s over the last 12 months.

RGEN's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for GH (100) in the Medical Or Nursing Services industry. This means that RGEN’s stock grew significantly faster than GH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GHRGEN
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 1 day ago
76%
Declines
ODDS (%)
Bearish Trend 17 days ago
82%
Bearish Trend 24 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
63%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
GH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPLIX21.590.18
+0.84%
NYLI Epoch U.S. Equity Yield Inv Class
NWFFX85.490.18
+0.21%
American Funds New World F1
ASMMX28.39N/A
N/A
Invesco Summit A
HWMIX51.11N/A
N/A
Hotchkis & Wiley Mid-Cap Value I
DSHFX11.84N/A
N/A
Brinker Capital Destinations Shelter I

GH and

Correlation & Price change

A.I.dvisor indicates that over the last year, GH has been loosely correlated with TWST. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then TWST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GH
1D Price
Change %
GH100%
-0.72%
TWST - GH
51%
Loosely correlated
+4.09%
VCYT - GH
49%
Loosely correlated
+1.78%
NTRA - GH
47%
Loosely correlated
-1.06%
RGEN - GH
44%
Loosely correlated
+1.26%
BLFS - GH
43%
Loosely correlated
+10.28%
More

RGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
+1.26%
DHR - RGEN
66%
Closely correlated
+2.01%
A - RGEN
64%
Loosely correlated
+1.63%
BIO - RGEN
58%
Loosely correlated
+0.05%
BRKR - RGEN
58%
Loosely correlated
+1.62%
RVTY - RGEN
58%
Loosely correlated
+1.62%
More